Small sample of 4 regions suggests higher ICU use after COVID jabs
Comparing the exact same weeks of each year
Government officials, in response to the COVID jabs completely failing to prevent the spread of infection — possibly even increasing the spread of the disease — then retreated to the more remote claim that the jabs prevent severe hospitalization and death.
But that claim was never tested.
The best indicator of “severe hospitalization” is the rate of admissions into intensive care units (ICU).
This first investigation into whether evidence supports the claim is a small sample of just 4 regions: Greece, Ireland, Israel, and Norway. There are only about 40 weeks from 2020 where good data exist prior to jab rollouts, so that you could compare those 40 weeks to the same 40 weeks in other years.
ICU admissions began being tracked by mid-March in many regions, but by mid-December, some regions had rolled out the COVID jab, so the “no jab” time-window for 2020 should not extend to the end of the year — unless you individually verify a later jab rollout.
Here are the results of comparing the exact same weeks of the year in 2020 and 2021, with some perspective given by a 31-week average weekly ICU admission rate for influenza (2014/15 season):
Note what happened to ICU admissions in Greece (far left) after COVID jabs rolled out. In 3 of the 4 regions, ICU admission rates rose after COVID jabs rolled out.
But even in Israel where average weekly ICU admissions went down, the aggregated numbers (the 40-week average) hides the fact that ICU admission rates track in lock-step with COVID jab administration rates (data not shown).
Here is the same graph with notes:
Ireland and Norway had no “pandemic signal” when the 40 weeks of ICU admission rates were averaged. Their ICU admissions for these 9 months were similar to that seen with flu, although the flu season has a shifted time-window, such that the flu estmate showing will at least slightly make flu appear more relatively virulent.
All weeks for the flu estimate were flu-season weeks typically reported by CDC (Week 40 to Week 17 of the next year) — but COVID estimates included summer weeks.
For 2022, only 35 weeks of data were available to compare to 2020. Because those 35 weeks include even less of the winter season, the flu numbers at far right will be even less reliable as a comparator:
To visualize where the flu numbers at far right should actually be — if the exact same 35 weeks of the year were used for flu at right like for COVID at left — then the bar heights for flu at right would shorten by about a third.
Note how this shows that Norway went from being better than flu under COVID alone (no jab), to being worse than flu under “COVID + jab.” Here is the same graph with notes:
This small sample suggests that COVID jabs do not cut ICU admission rates, though it was too small to reach statistic significance in a paired t-test for the mean of individual differences. The trend showing up here is one where the COVID jabs increase (not decrease) the average of weekly ICU admission rates.
Here are the 4 regions tracked for the time windows shown above and COVID jab rollouts are located right after the “y” in the blue “+Add country” tab right above the first big peak:
In aggregate, the incremental area under the 4 curves — the overall COVID ICU burden — is definitely greater after the COVID jabs rolled out than it was before them. For perspective, the worst week in recent history from flu was the beginning of 2018 — a week when there were 15.5 ICU hospitalizations per million in the US.
Reference
[weekly COVID ICU admissions per million] — OWID. https://ourworldindata.org/covid-hospitalizations
[weekly flu hospitalizations overall] — CDC. https://gis.cdc.gov/grasp/fluview/fluhosprates.html
[2014/15 fraction of all flu hospitalizations which were ICU hospitalizations] — O’Halloran AC, Holstein R, Cummings C, et al. Rates of influenza-associated hospitalization, intensive care unit admission, and in-hospital death by race and ethnicity in the United States from 2009 to 2019. JAMA Netw Open. 2021;4(8):e2121880. doi: 10.1001/jamanetworkopen.2021.21880